Browse hierarchy: [Microbiology (MI)](/submissions/MI) → [Subpart D — Serological Reagents](/submissions/MI/subpart-d%E2%80%94serological-reagents) → [21 CFR 866.3372](/submissions/MI/subpart-d%E2%80%94serological-reagents/866.3372) → MWA — System, Nucleic Acid Amplification, Mycobacterium Tuberculosis Complex

# MWA · System, Nucleic Acid Amplification, Mycobacterium Tuberculosis Complex

_Microbiology · 21 CFR 866.3372 · Class 2_

**Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/MWA

## Overview

- **Product Code:** MWA
- **Device Name:** System, Nucleic Acid Amplification, Mycobacterium Tuberculosis Complex
- **Regulation:** [21 CFR 866.3372](/submissions/MI/subpart-d%E2%80%94serological-reagents/866.3372)
- **Device Class:** 2
- **Review Panel:** [Microbiology](/submissions/MI)

## Identification

Nucleic acid-based in vitro diagnostic devices for the detection of Mycobacterium tuberculosis complex in respiratory specimens are qualitative nucleic acid-based in vitro diagnostic devices intended to detect Mycobacterium tuberculosis complex nucleic acids extracted from human respiratory specimens. These devices are non-multiplexed and intended to be used as an aid in the diagnosis of pulmonary tuberculosis when used in conjunction with clinical and other laboratory findings. These devices do not include devices intended to detect the presence of organism mutations associated with drug resistance. Respiratory specimens may include sputum (induced or expectorated), bronchial specimens (e.g., bronchoalveolar lavage or bronchial aspirate), or tracheal aspirates.

## Classification Rationale

Class II (special controls). The special control for this device is the FDA document entitled “Class II Special Controls Guideline: Nucleic Acid-Based In Vitro Diagnostic Devices for the Detection of Mycobacterium tuberculosis Complex in Respiratory Specimens.” For availability of the guideline document, see § 866.1(e).

## Special Controls

*Classification.* Class II (special controls). The special control for this device is the FDA document entitled “Class II Special Controls Guideline: Nucleic Acid-Based In Vitro Diagnostic Devices for the Detection of*Mycobacterium tuberculosis* Complex in Respiratory Specimens.” For availability of the guideline document, see § 866.1(e).

## Recent Cleared Devices (2 of 2)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [P940040](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/MWA/P940040.md) | AMPLICOR (TM) MYCOBACTERIUM TUBERCULOSIS TEST | Roche Molecular Systems, Inc. | Nov 26, 1996 | APWD |
| [P940034](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/MWA/P940034.md) | GEN-PROBE(R) AMPLIFIED MYCOBACTERIUM TUBERCULOSIS DIRECT TEST (MTD TEST) | Gen-Probe, Inc. | Dec 15, 1995 | APRL |

## Top Applicants

- Gen-Probe, Inc. — 1 clearance
- Roche Molecular Systems, Inc. — 1 clearance

---

**Source:** [https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/MWA](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/MWA)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com